Citius Pharmaceuticals Inc vs JPMorgan Ultra Short Income ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M), while JPMorgan Ultra Short Income ETF trades at $50.47. Which is the better fit depends on your goals.
| CTXR | JPST | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $50.78 |
52-Week Low | $0.48 | $50.40 |
Enterprise Value | $16.23M | — |
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →